Black Diamond Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Black Diamond Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker
The story matters when it changes Black Diamond Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: official volume, pricing, inventory and segment margin.Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?
The story matters when it changes Black Diamond Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise
The story matters when it changes Black Diamond Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest BDTX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Black Diamond Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →